CHU de NICE
Nice, Alpes Maritimes, 06000, France
Location status: Recruiting
NCT Number: NCT07266857
This study is a non-interventional observational pilot analysis assessing the possible impact of an educational programme (e-Bug) on parental consent and HPV vaccination uptake during the 2023-2024 and 2024-2025 national school-based HPV vaccination campaigns in France. The study focuses on one middle school in the Alpes-Maritimes department where teachers and the school nurse had been previously trained on HPV and used e-Bug educational resources in class as part of routine health education. No research-related intervention was conducted, and the educational programme was not introduced or modified for the purpose of the study. Only aggregated and anonymised vaccination data were used. These data were routinely collected by the Regional Health Agency (ARS PACA) as part of the national vaccination programme and transmitted for analysis. Aggregated data from the pilot school were compared with departmental-level outcomes to describe whether an upstream educational approach may be associated with improved parental acceptance and higher HPV vaccination coverage. This study aims to contribute to the understanding of educational determinants of vaccine uptake in a real-life school setting without involving any participant recruitment or individual data collection.
Interested in participating?
Request InfoAll sexes
Observational
Nice, Alpes Maritimes, 06000, France
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Consent for HPV vaccination
Time frame: From (start of 2023-2024 HPV vaccination campaign) to(end of 2024-2025)
e-Bug educational programme
Time frame: From (start of 2023-2024 HPV vaccination campaign) to(end of 2024-2025)
Aggregated proportion of parents providing positive consent for HPV vaccination in the pilot school, compared with aggregated departmental consent rates collected by ARS PACA during the 2023-2024 and 2024-2025 school-based campaigns.
Time frame: From (start of 2023-2024 HPV vaccination campaign) to(end of 2024-2025)
Aggregated rate of returned parental authorisation forms (regardless of response: yes/no) in the pilot school compared with departmental response rates.
Contact information is provided by the study sponsor or research team.
Centre Hospitalier Universitaire de Nice
Other
Pilot Observational Comparative Study Evaluating the Impact of the e-Bug Educational Programme on Parental Consent and HPV Vaccination Coverage During the National School-Based Vaccination Campaign in a Middle School in the Alpes-Maritimes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05266898
Acquired Immunodeficiency Syndrome, Anal Intraepithelial Neoplasia
New Orleans, Louisiana, United States
View Trial DetailsNCT06538480
Communicable Diseases, DNA Virus Infections
Atlanta, Georgia, United States
View Trial DetailsNCT05592626
Abdominal Neoplasm, Abdominal Neoplasms
Loma Linda, California, United States
View Trial DetailsNCT05453006
Cervical Cancer, Communicable Diseases
Minneapolis, Minnesota, United States
View Trial Details